Merck's Keytruda First-Line Improves Esophageal Cancer Survival

Merck & Co., Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab), combined with chemotherapy, has improved the two primary endpoints, overall survival and progression-free survival (PFS), when used first line for the treatment of locally advanced or metastatic esophageal cancer, according to the results of an interim analysis of the pivotal Phase III KEYNOTE-590 trial.

Further details of the clinical benefit associated with Keytruda in earlier lines of therapy than the currently approved esophageal cancer indication have been submitted for presentation at the European Society...